Sekisui Chemical Co., Ltd. (SKSUY) Q3 2025 Earnings Call Prepared Remarks Transcript

Sekisui Chemical reported Q3 net sales of JPY 330.1 billion, a record high, while operating profit fell to JPY 27.5 billion and ordinary profit declined to JPY 31.8 billion year on year. Net profit was reduced by a JPY 14.9 billion impairment tied to dismantling the Kuji biorefinery plant after a completed demonstration experiment. The company also reaffirmed its buyback execution, with a 10 million-share, JPY 30 billion second-half repurchase program and 14 million shares targeted for the full year.

Analysis

The key read-through is that this is a quality-of-earnings cleanup rather than a demand inflection story. A weaker yen is providing visible EPS support, but the bigger economic signal is that management is willing to exit a non-core biorefinery experiment and crystallize an impairment now, which should reduce future capital drag and improve ROIC optics over the next 12-18 months. That kind of pruning usually matters more than the headline profit dip because it frees up balance sheet capacity for higher-return polymer/materials businesses and supports the ongoing buyback.

The buyback remains the clearest near-term support for the equity, but investors should focus on execution pace rather than authorization size. If they complete the repurchase into a still-soft macro tape, the stock gets a mechanical EPS floor and lower free-float over the next 1-2 quarters; if they slow it, sentiment will likely fade because the market is implicitly relying on capital return to offset cyclical earnings pressure. Currency is an additional second-order tailwind: each incremental yen weakness meaningfully lifts operating profit, so Sekisui behaves like a low-volatility FX hedge within Japanese industrials.

The more interesting contrarian angle is that the impairment may be a positive signal for peers rather than a warning sign. It suggests management is becoming more disciplined on experimental capex, which should pressure other Japanese industrials with lingering “green innovation” portfolios to either prove economics or take charges; that can widen valuation dispersion between disciplined allocators and story-stock capital spenders. Over the next 3-6 months, the main reversal risks are a sharper yen rally and any evidence that core segment margins are deteriorating faster than FX can compensate.

Key Decisions for Investors

• Long SKSUY on pullbacks over the next 1-3 months as a capital-return + FX beneficiary; target a 8-12% rerating if buyback execution remains on schedule and yen stays weak. Risk: a 5-7% yen appreciation can quickly offset several quarters of buyback support.
• Pair trade: long SKSUY / short a Japan industrial with higher experimental capex and weaker capital discipline over 3-6 months. The trade is a ROIC-dispersion play; expect the market to reward companies that are exiting non-core projects instead of funding them.
• Buy SKSUY call spreads into yen weakness over the next quarter. The option structure captures the asymmetric earnings sensitivity to FX while limiting downside if the currency mean-reverts.
• Reduce exposure to Japanese exporters with similar FX beta but less visible buyback support if the yen remains above prior consensus levels; SKSUY’s repurchase should create relative outperformance versus peers with no capital return catalyst.
• Monitor for follow-through on segment margin disclosure in the next print; if core margins hold while the non-core drag disappears, add to the position into the next earnings cycle.